FDA approves Moderna's mRNA flu shot, first of its kind

Published Aug 6, 04:31 PM UTC

Editorial responsibility

Prepared by: WorldAttention Editorial Systems
Human review: No named human review is recorded for this page.
Automated steps: Source reporting is collected, normalized, translated or condensed automatically when needed.
Page status: Automatically published source-backed update

How automation and AI are used · Report a correction or rights issue

The U.S. Food and Drug Administration (FDA) has approved Moderna's mRNA-based influenza vaccine, marking the first mRNA flu shot to receive regulatory clearance. The approval follows a tumultuous review process, with the vaccine initially facing setbacks and skepticism. The shot is designed to target seasonal flu strains and is expected to be available for the upcoming flu season, particularly for older adults who are at higher risk. The decision is seen as a significant milestone for mRNA technology beyond COVID-19, though some experts caution about efficacy and rollout challenges. The approval comes amid broader debates over vaccine mandates and public health policy, including criticism of past decisions by figures like Robert F. Kennedy Jr. to cancel mRNA vaccine projects.

Source

People and interests

FDA Robert F. Kennedy Jr.